Hansa Biopharma receives positive opinion for transplant asset in EU: "Amazing"
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommends conditional approval of Hansa Biopharma's main asset Idefirix in EU. The Swedish biotech firm expects to launch the drug by approximately fourth quarter of 2020.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY IDA LØJMAND
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.